CALQUENCE
acalabrutinib
- Strength
- 100 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor
AstraZeneca Pharmaceuticals LP
acalabrutinib
Listed by AstraZeneca Pharmaceuticals LP
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Kinase Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 0310-3512 |
| FDA application | NDA216387 |
| RxNorm concept | 2607734 |
| Package sizes listed | 2 |
| Marketed since | August 2022 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.